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11. Drug addiction is a brain disease that affects 
behavior. Drug addiction has well-recognized cognitive, behavioral, 
and physiological characteristics that contribute to continued use of 
drugs despite the harmful consequences. Scientists have also found 
that chronic drug abuse alters the brain’s anatomy and chemistry and 
that these changes can last for months or years after the individual 
has stopped using drugs. This transformation may help explain why 
addicted persons are at a high risk of relapse to drug abuse even 
after long periods of abstinence and why they persist in seeking drugs 
despite the consequences.
2. Recovery from drug addiction requires 
effective treatment, followed by management of the 
problem over time. Drug addiction is a serious problem that 
can be treated and managed throughout its course. Effective drug 
abuse treatment engages participants in a therapeutic process, retains 
them in treatment for an appropriate length of time, and helps them 
learn to maintain abstinence. Multiple episodes of treatment may be 
required. Outcomes for drug abusing offenders in the community can 
be improved by monitoring drug use and by encouraging continued 
participation in treatment.
3. Treatment must last long enough to produce 
stable behavioral changes. In treatment, the drug abuser 
is taught to break old patterns of thinking and behaving and to learn 
new skills for avoiding drug use and criminal behavior. Individuals with 
severe drug problems and co-occurring disorders typically need longer 
treatment (e.g., a minimum of 3 months) and more comprehensive 
services. Early in treatment, the drug abuser begins a therapeutic 
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2process of change. In later stages, he or she addresses other 
problems related to drug abuse and learns how to manage them as 
well.
4. Assessment is the first step in treatment.  
A history of drug or alcohol use may suggest the need to conduct a 
comprehensive assessment to determine the nature and extent of 
an individual’s drug problems, establish whether problems exist in 
other areas that may affect recovery, and enable the formulation of 
an appropriate treatment plan. Personality disorders and other mental 
health problems are prevalent in offender populations; therefore, 
comprehensive assessments should include mental health evaluations 
with treatment planning for these problems.
5. Tailoring services to fit the needs of the 
individual is an important part of effective drug 
abuse treatment for criminal justice populations. 
Individuals differ in terms of age, gender, ethnicity and culture, 
problem severity, recovery stage, and level of supervision needed. 
Individuals also respond differently to different treatment approaches 
and treatment providers. In general, drug treatment should address 
issues of motivation, problemsolving, and skill-building for resisting 
drug use and criminal behavior. Lessons aimed at supplanting 
drug use and criminal activities with constructive activities and 
at understanding the consequences of one’s behavior are also 
important to include. Tailored treatment interventions can facilitate 
the development of healthy interpersonal relationships and improve 
the participant’s ability to interact with family, peers, and others in 
the community.
6. Drug use during treatment should be carefully 
monitored. Individuals trying to recover from drug addiction may 
experience a relapse, or return to drug use. Triggers for drug relapse 
are varied; common ones include mental stress and associations with 
peers and social situations linked to drug use. An undetected relapse 
can progress to serious drug abuse, but detected use can present 
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urinalysis or other objective methods, as part of treatment or criminal 
justice supervision, provides a basis for assessing and providing 
feedback on the participant’s treatment progress. It also provides 
opportunities to intervene to change unconstructive behavior—
determining rewards and sanctions to facilitate change,  
and modifying treatment plans according to progress.
7. Treatment should target factors that are 
associated with criminal behavior. “Criminal thinking” is 
a combination of attitudes and beliefs that support a criminal lifestyle 
and criminal behavior, such as feeling entitled to have things one’s 
own way, feeling that one’s criminal behavior is justified, failing to 
accept responsibility for one’s actions, and consistently failing to 
anticipate or appreciate the consequences of one’s behavior. This 
pattern of thinking often contributes to drug use and criminal behavior. 
Treatment that provides specific cognitive skills training to help 
individuals recognize errors in judgment that lead to drug abuse and 
criminal behavior may improve outcomes.
8. Criminal justice supervision should incorporate 
treatment planning for drug abusing offenders, and 
treatment providers should be aware of correctional 
supervision requirements. The coordination of drug abuse 
treatment with correctional planning can encourage participation in 
drug abuse treatment and can help treatment providers incorporate 
correctional requirements as treatment goals. Treatment providers 
should collaborate with criminal justice staff to evaluate each 
individual’s treatment plan and ensure that it meets correctional 
supervision requirements, as well as that person’s changing needs, 
which may include housing and child care; medical, psychiatric, and 
social support services; and vocational and employment assistance. 
For offenders with drug abuse problems, planning should incorporate 
the transition to community-based treatment and links to appropriate 
post-release services to improve the success of drug treatment 
and re-entry. Abstinence requirements may necessitate a rapid 
clinical response, such as more counseling, targeted intervention, 
4or increased medication, to prevent relapse. Ongoing coordination 
between treatment providers and courts or parole and probation 
officers is important in addressing the complex needs of these 
re-entering individuals.
9. Continuity of care is essential for drug abusers 
re-entering the community. Offenders who complete prison-
based treatment and continue with treatment in the community have 
the best outcomes. Continuing drug abuse treatment helps the 
recently released offender deal with problems that become relevant 
after release, such as learning to handle situations that could lead 
to relapse, learning how to live drug-free in the community, and 
developing a drug-free peer support network. Treatment in prison or 
jail can begin a process of therapeutic change, resulting in reduced 
drug use and criminal behavior post-incarceration. Continuing drug 
treatment in the community is essential to sustaining these gains.
10. A balance of rewards and sanctions 
encourages pro-social behavior and treatment 
participation. When providing correctional supervision of 
individuals participating in drug abuse treatment, it is important 
to reinforce positive behavior. Nonmonetary “social reinforcers,” 
such as recognition for progress or sincere effort, can be effective, 
as can graduated sanctions that are consistent, predictable, and 
clear responses to noncompliant behavior. Generally, less punitive 
responses are used for early and less serious noncompliance, 
with increasingly severe sanctions issuing from continued problem 
behavior. Rewards and sanctions are most likely to have the desired 
effect when they are perceived as fair and when they swiftly follow the 
targeted behavior.
11. Offenders with co-occurring drug abuse and 
mental health problems often require an integrated 
treatment approach. High rates of mental health problems are 
found both in offender populations and in those with substance abuse 
problems. Drug abuse treatment can sometimes address depression, 
anxiety, and other mental health problems. Personality, cognitive, 
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disrupt drug treatment. The presence of co-occurring disorders may 
require an integrated approach that combines drug abuse treatment 
with psychiatric treatment, including the use of medication. Individuals 
with either a substance abuse or mental health problem should be 
assessed for the presence of the other.
12. Medications are an important part of 
treatment for many drug abusing offenders. 
Medicines such as methadone, buprenorphine, and extended-release 
naltrexone have been shown to reduce heroin use and should be 
made available to individuals who could benefit from them. Effective 
use of medications can also be instrumental in enabling people 
with co-occurring mental health problems to function successfully 
in society. Behavioral strategies can increase adherence to 
medication regimens.
13. Treatment planning for drug abusing 
offenders who are living in or re-entering the 
community should include strategies to prevent 
and treat serious, chronic medical conditions, such 
as HIV/AIDS, hepatitis B and C, and tuberculosis. 
The rates of infectious diseases, such as hepatitis, tuberculosis, and 
HIV/AIDS, are higher in drug abusers, incarcerated offenders, and 
offenders under community supervision than in the general population. 
Infectious diseases affect not just the offender, but also the criminal 
justice system and the wider community. Consistent with Federal 
and State laws, drug-involved offenders should be offered testing for 
infectious diseases and receive counseling on their health status and 
on ways to modify risk behaviors. Probation and parole officers who 
monitor offenders with serious medical conditions should link them 
with appropriate health care services, encourage compliance with 
medical treatment, and re-establish their eligibility for public health 
services (e.g., Medicaid, county health departments) before release 
from prison or jail.
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9From the time it was established 
in 1974, the National Institute 
on Drug Abuse (NIDA) has 
supported research on drug 
abuse treatment for people 
involved with the criminal justice 
system.
Findings show unequivocally that providing comprehensive drug 
abuse treatment to criminal offenders works, reducing both drug 
abuse and criminal recidivism. The substantial prison population in 
the United States is attributable in large part to drug-related offenses 
and is accompanied by high rates of recidivism. As such,  
it is a matter of public health and safety to make drug abuse 
treatment a key component of the criminal justice system. Indeed, 
addressing the treatment needs of substance abusing offenders 
is critical to reducing overall crime and other drug-related societal 
burdens, such as lost job productivity and family disintegration.
Scientific research shows that drug abuse treatment can work 
even when an individual enters it under legal mandate. However, 
only a small percentage of those who need treatment actually 
receive it, and often the treatment provided is inadequate. To be 
effective, treatment must begin in prison and be sustained after 
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release through participation in community treatment programs. By 
engaging in a continuing therapeutic process, individuals can learn 
how to avoid relapse and withdraw from a life of crime.
As reflected in our collaborative Criminal Justice–Drug Abuse 
Treatment Studies (CJ–DATS) Initiative, NIDA is committed to 
working across organizational boundaries to improve substance 
abuse treatment services. Multiple studies from different scientific 
disciplines have helped us understand the basic neurobiology of 
addiction, along with what constitutes effective treatment. Now 
we are at the point where the implementation of evidence-based 
treatment principles is called for within the criminal justice system to 
improve public health and public safety by reducing both drug use 
and crime.
This booklet—a complement to NIDA’s Principles of Drug Addiction 
Treatment: A Research-Based Guide—is intended to describe the 
treatment principles and research findings that have particular 
relevance to the criminal justice community and to treatment 
professionals working with drug abusing offenders. It is divided into 
three main sections: (1) research findings on addicted offenders 
distilled into 13 essential principles (see pages 1–5), (2) a series of 
frequently asked questions (FAQs) about drug abuse treatment for 
those involved with the criminal justice system, and (3) a resource 
section that provides Web sites for additional information. This 
booklet and other resources on drug abuse and the criminal justice 
system are available on NIDA’s Web site at http://www.drugabuse.
gov/drugpages/cj.html. 
With the release of this landmark publication’s revised edition, we 
are optimistic that correctional agencies have begun to understand 
how drug treatment programs are helping achieve public health and 
safety goals for the Nation.
Nora D. Volkow, M.D.
Director
National Institute on Drug Abuse
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The connection between 
drug abuse and crime is well 
known.
Drug abuse is implicated in at least three types of drug-
related offenses: (1) offenses defined by drug possession or 
sales, (2) offenses directly related to drug abuse (e.g., stealing 
to get money for drugs), and (3) offenses related to a lifestyle 
that predisposes the drug abuser to engage in illegal activity, for 
example, through association with other offenders or with illicit 
markets. Individuals who use illicit drugs are more likely to commit 
crimes, and it is common for many offenses, including violent crimes, 
to be committed by individuals who had used drugs or alcohol prior 
to committing the crime, or who were using at the time of the offense.
According to 2012 statistics from the Department of Justice’s 
(DOJ’s) Bureau of Justice Statistics (BJS), the total correctional 
population is 6,937,600, with 4,794,000 individuals on probation or 
under parole supervision, and drug law violations accounting for the 
most common type of criminal offense (Glaze and Herberman 2013). 
In a survey of State and Federal prisoners, BJS estimated that about 
half of the prisoners met Diagnostic and Statistical Manual for Mental 
Disorders (DSM) criteria for drug abuse or dependence, and yet 
fewer than 20 percent who needed treatment received it (Chandler 
et al. 2009; Mumola and Karberg 2006). Of those surveyed, 14.8 
percent of State and 17.4 percent of Federal prisoners reported 
having received drug treatment since admission (Mumola and 
Karberg 2006). 
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Juvenile justice systems also report high levels of drug abuse. 
In 2008, approximately 10 percent of the estimated 2.1 million 
juvenile arrests were for drug abuse or underage drinking violations 
(Puzzanchera 2009). As many as two-thirds of detained juveniles 
may have a substance use disorder (SUD); female juveniles who 
enter the system generally have higher SUD rates than males 
(McClelland et al. 2004a). 
Although the past several decades 
have witnessed an increased interest 
in providing substance abuse 
treatment services for criminal 
justice offenders, only a small 
percentage of offenders has access 
to adequate services, especially in jails 
and community correctional facilities 
(Taxman et al. 2007; Sabol et al. 2010). Not 
only is there a gap in the availability of these services for offenders, 
but often there are few choices in the types of services provided. 
Treatment that is of insufficient quality and intensity or that is not 
well suited to the needs of offenders may not yield meaningful 
reductions in drug use and recidivism. Untreated substance abusing 
offenders are more likely than treated offenders to relapse to drug 
abuse and return to criminal behavior. This can lead to re-arrest 
and re-incarceration, jeopardizing public health and public safety 
and taxing criminal justice system resources. Treatment is the most 
effective course for interrupting the drug abuse/criminal justice cycle 
for offenders with drug abuse problems.
Drug abuse treatment can be incorporated into criminal justice 
settings in a variety of ways. Examples include treatment in prison 
followed by community-based treatment after release; drug courts 
that blend judicial monitoring and sanctions with treatment by 
imposing treatment as a condition of probation; and treatment under 
parole or probation supervision. Drug abuse treatment can benefit 
from the cross-agency coordination and collaboration of criminal 
justice professionals, substance abuse treatment providers, and 
other social service agencies. By working together, the criminal 
justice and treatment systems can optimize resources to benefit the 
health, safety, and well-being of the individuals and communities 
they serve.
Treatment offers 
the best alternative 
for interrupting the 
drug abuse/criminal 
justice cycle.
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1. Why do people involved in the criminal 
justice system continue abusing drugs?
The answer to this perplexing question spans basic neurobiological, 
psychological, social, and environmental factors. The repeated use of 
addictive drugs eventually changes how the brain functions. Resulting 
brain changes, which accompany the transition from voluntary to 
compulsive drug use, affect the brain’s natural inhibition and reward 
centers, causing the 
addicted person to 
use drugs in spite of 
the adverse health, 
social, and legal 
consequences (Baler 
and Volkow 2006; 
Volkow et al. 2010; 
and Chandler et 
al. 2009). Craving 
for drugs may be 
triggered by contact 
with the people, 
places, and things 
associated with prior 
drug use, as well as 
by stress. Forced 
abstinence (when it occurs) is not treatment, and it does not cure 
addiction. Abstinent individuals must still learn how to avoid relapse, 
including those who may have been abstinent for a long period of time 
while incarcerated.
FREQUENTLY ASKED 
QUESTIONS (FAQS)
Normal
Addictive drugs cause 
long-lasting changes in the brain
Cocaine Abuser 
(100 days of 
abstinence)
PET scans showing glucose metabolism in healthy 
(normal) and cocaine-addicted brains. Even after 100 
days of abstinence, glucose metabolism has not returned 
to normal levels.
Source: Volkow et al., 1992, 1993.
Cocaine Abuser 
(10 days of 
abstinence) 
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Potential risk factors for released offenders include pressures 
from peers and family members to return to drug use and a criminal 
lifestyle. Tensions of daily life—violent associates, few opportunities 
for legitimate employment, lack of safe housing, and even the need 
to comply with correctional supervision conditions—can also create 
stressful situations that can precipitate a relapse to drug use.
Research on how the brain is affected by drug abuse promises 
to teach us much more about the mechanics of drug-induced brain 
changes and their relationship to addiction. Research also reveals 
that with effective drug abuse treatment, individuals can overcome 
persistent drug effects and lead healthy, productive lives.
2. Why should drug abuse treatment 
be provided to offenders?
The case for treating drug abusing offenders is compelling. Drug 
abuse treatment improves outcomes for drug abusing offenders and 
has beneficial effects for public health and safety. Effective treatment 
decreases future drug use and drug-related criminal behavior, can 
improve the individual’s relationships with his or her family, and may 
improve prospects for employment. In addition, it can save lives: A 
retrospective study of more than 30,000 Washington State inmates 
found that during the first 2 weeks after release, the risk of death 
among former inmates was more than 12 times that among other 
residents, with drug overdose being the leading cause (Binswanger et 
al. 2007).
Outcomes for substance abusing individuals can be improved when 
criminal justice personnel work in tandem with treatment providers 
on drug abuse treatment needs and supervision requirements. 
Treatment needs that can be assessed after arrest include substance 
abuse severity, mental health problems, and physical health. Defense 
attorneys, prosecutors, and judges need to work together during the 
prosecution and sentencing phases of the criminal justice process 
to determine suitable treatment programs that meet the offender’s 
needs. Through drug courts, diversion programs, pretrial release 
programs that are conditional on treatment, and conditional probation 
with sanctions, the offender can participate in community-based drug 
FREQUENTLY ASKED QUESTIONS
17
abuse treatment while under criminal justice supervision. In some 
instances, the judge may recommend that the offender participate 
in treatment while serving jail or prison time or require it as part of 
continuing correctional supervision post-release.
3. How effective is drug abuse treatment 
for criminal justice-involved individuals?
Treatment is an effective intervention for drug abusers, including 
those who are involved with the criminal justice system. However, the 
effectiveness of drug treatment depends on both the individual and the 
program, and on whether interventions 
and treatment services are available 
and appropriate for the individual’s 
needs. To alter attitudes, beliefs, 
and behaviors that support 
drug use, the drug abuser must 
engage in a therapeutic change 
process, which may include 
medications to help prevent relapse. 
Longitudinal outcome studies find 
that those who participate in community-based drug abuse treatment 
programs commit fewer crimes than those who do not participate 
(Prendergast et al. 2002; Butzin et al. 2006; and Kinlock et al. 2009).
4. Are all drug abusers in the criminal justice 
system good candidates for treatment?
A history of drug use does not in itself indicate the need for drug 
abuse treatment. Offenders who meet drug dependence criteria 
should be given higher priority for treatment than those who do 
not. Less intensive interventions, such as drug abuse education 
or self-help group participation, may be appropriate for those not 
meeting criteria for drug dependence. Services such as family-
based interventions for juveniles, psychiatric treatment, or cognitive-
behavioral interventions for changing “criminal thinking” may be a 
higher priority for some offenders, and individuals with mental health 
problems may require specialized services (see FAQ Nos. 6 and 12).
Outcomes can be 
improved when criminal 
justice personnel work 
in tandem with treatment 
providers.
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Low motivation to participate in treatment or to end drug abuse 
should not preclude access to treatment if other criteria are met. 
Motivational enhancement interventions may be useful in these 
cases. Examples include motivational interviewing and contingency 
management techniques, which often provide tangible rewards in 
exchange for meeting program goals. Legal pressure that encourages 
abstinence and treatment participation may also help these individuals 
by improving retention and prompting longer treatment stays.
Drug abuse treatment is also effective for offenders who have 
a history of serious and violent crime, particularly if they receive 
intensive, targeted services. The economic benefits in avoided crime 
costs and those of crime victims (e.g., medical costs, lost earnings, 
and loss in quality of life) may be substantial for these high-risk 
offenders. Treating them requires a high degree of coordination 
between drug abuse treatment providers and criminal justice 
personnel to ensure that the prisoners receive needed treatment and 
other services that will help prevent criminal recidivism.
5. Is legally mandated treatment effective?
Often, the criminal justice system can apply legal pressure to 
encourage offenders to participate in drug abuse treatment; or 
treatment can be mandated through a drug court or as a condition 
of pretrial release, probation, or parole. A large percentage of those 
admitted to drug abuse treatment cite legal pressure as an important 
reason for seeking treatment. Most studies suggest that outcomes 
for those who are legally pressured to enter 
treatment are as good as or better than 
outcomes for those who entered treatment 
without legal pressure. Individuals under 
legal pressure also tend to have higher 
attendance rates and remain in treatment 
for longer periods, which can also have a 
positive impact on treatment outcomes.
Legal pressure can 
increase treatment 
attendance and 
improve retention.
FREQUENTLY ASKED QUESTIONS
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6. Are relapse risk factors different in 
offender populations? How should drug abuse 
treatment deal with these risk factors?
Often, drug abusing offenders have problems in other areas. 
Examples include family difficulties, limited social skills, educational 
and employment problems, mental health disorders, infectious 
diseases, and other medical issues. Treatment should take these 
problems into account, because they can increase the risk of drug 
relapse and criminal recidivism if left unaddressed.
Stress is often a contributing factor 
to relapse, and offenders who are 
re-entering society face many 
challenges and stressors, 
including reuniting with family 
members, securing housing, and 
complying with criminal justice 
supervision requirements. Even 
the many daily decisions that most 
people face can be stressful for those 
recently released from a highly controlled prison environment.
Other threats to recovery include a loss of support from family or 
friends, which incarcerated people may experience. Drug abusers 
returning to the community may also encounter people from their 
lives who are still involved in drugs or crime and be enticed to resume 
a criminal and drug using lifestyle. Returning to environments or 
activities associated with prior drug use may trigger strong cravings 
and cause a relapse. A coordinated approach by treatment and 
criminal justice staff provides the best way to detect and intervene with 
these and other threats to recovery. In any case, treatment is needed 
to provide the skills necessary to avoid or cope with situations that 
could lead to relapse.
Treatment staff should identify the offender’s unique relapse risk 
factors and periodically re-assess and modify the treatment plan 
as needed. Generally, continuing or re-emerging drug use during 
treatment requires a clinical response—either increasing the amount 
or level of treatment, or changing the treatment intervention.
Returning to environments
associated with drug use 
may trigger cravings and 
cause a relapse.
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7. What treatment and other health services 
should be provided to drug abusers involved 
with the criminal justice system?
One of the goals of treatment planning is to match evidence-based 
interventions to individual needs at each stage of drug treatment. Over 
time, various combinations of treatment services may be required. 
Evidence-based interventions include cognitive-behavioral therapy to 
help participants learn positive social and coping skills, contingency 
management approaches to reinforce positive behavioral change, and 
motivational enhancement to increase treatment engagement and 
retention. In those addicted to opioid drugs, agonist/partial agonist 
medications can also help normalize brain function, and antagonist 
medications can facilitate abstinence. For juvenile offenders, 
treatments that involve the family and other aspects of the drug 
abuser’s environment have established efficacy.
Drug abuse treatment plans for incarcerated offenders can facilitate 
successful re-entry into the community by incorporating relevant 
transition plans and services. Drug abusers often have mental and 
physical health, family counseling, parenting, educational, and 
vocational needs, so medical, psychological, and social services are 
often crucial components of successful treatment. Case management 
approaches can be used to provide assistance in obtaining and 
integrating drug abuse treatment with community services.
8. How long should drug abuse treatment last for 
individuals involved in the criminal justice system?
While individuals progress through drug abuse treatment at 
different rates, one of the most reliable findings in treatment 
research is that lasting reductions in criminal activity and drug 
abuse are related to length of treatment. Generally, better outcomes 
are associated with treatment that lasts longer than 90 days, with 
treatment completers achieving the greatest reductions in drug 
abuse and criminal behavior. Again, legal pressure can improve 
retention rates. 
FREQUENTLY ASKED QUESTIONS
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A longer continuum of treatment may be indicated for individuals 
with severe or multiple problems. Research has shown that 
treatment provided in prison and continued in the community after 
release can reduce the risk of recidivism to criminal behavior as well 
as relapse to drug use. 
Early phases of treatment help the participant stop using drugs and 
begin a therapeutic process of change. Later stages address other 
problems related to drug abuse and, importantly, help the individual 
learn how to self-manage the drug problem.
Because addiction is a chronic disease, drug relapse and return 
to treatment are common features of recovery. Thus, treatment may 
need to extend over a long period across multiple episodes of care.
9. How can rewards and sanctions  
be used effectively with drug-involved  
offenders in treatment?
The systematic application of behavioral management principles 
underlying reward and punishment can help individuals reduce their 
drug use and criminal behavior. Rewards and sanctions are most 
likely to change behavior when they are certain to follow the targeted 
behavior, when they follow swiftly, and when they are perceived as fair. 
It is important to recognize and reinforce progress toward responsible, 
abstinent behavior. Rewarding positive behavior is more effective 
in producing long-term positive change than punishing negative 
behavior. Indeed, punishment alone is an ineffective public health 
and safety intervention for offenders whose crime is directly related to 
drug use (Leukefeld et al. 2002). Nonmonetary rewards such as social 
recognition can be as effective as monetary ones. A graduated range 
of rewards given for meeting predetermined goals can be an effective 
strategy. 
Contingency management strategies, proven effective in community 
settings, use voucher-based incentives or rewards, such as bus 
tokens, to reinforce abstinence (measured by negative drug tests) 
or to shape progress toward other treatment goals, such as program 
session attendance or compliance with medication regimens. 
Contingency management is most effective when the contingent 
reward closely follows the behavior being monitored. An intervention 
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tested by CJ-DATS researchers, called “Step’n Out,” used a 
contingency management approach whereby criminal justice staff 
monitored specific behaviors (e.g., abstinence, employment searches, 
and counseling attendance) and rewarded individuals who met 
agreed-upon goals with social acknowledgement (e.g., congratulatory 
letter from parole supervisor) and small material incentives (e.g., 
partial payment for clothes for job interviews). This approach improved 
parolees’ attendance at integrated community parole and addiction 
treatment sessions, as well as increased use of treatment and 
individual counseling services (Friedmann et al. 2009). 
Graduated sanctions, which invoke less punitive responses for early 
and less serious noncompliance and increasingly severe sanctions 
for more serious or continuing problems, can be an effective tool 
in conjunction with drug testing. The effective use of graduated 
sanctions involves consistent, predictable, and clear responses to 
noncompliant behavior. 
Drug testing can determine when an individual is having difficulties 
with recovery. The first response to drug use detected through 
urinalysis should be a clinical one—for example, increasing treatment 
intensity or switching to an alternative treatment. This often requires 
coordination between the criminal justice staff and the treatment 
provider. (Note that more intensive treatment should not be considered 
a sanction, but rather a routine progression in health care practice 
when a treatment appears less effective than expected.)
Behavioral contracting can employ both 
rewards and sanctions. A behavioral contract 
is an explicit agreement between the 
participant and the treatment provider 
or criminal justice monitor (or among all 
three) that specifies proscribed behaviors 
and associated sanctions, as well as 
positive goals and rewards for success. 
Behavioral contracting can instill a sense of 
procedural justice because both the necessary 
steps toward progress and the sanctions for violating the contract are 
specified and understood in advance.
It is important to 
recognize and 
reinforce progress 
toward responsible, 
abstinent behavior.
FREQUENTLY ASKED QUESTIONS
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10. What is the role of medications in 
treating substance abusing offenders?
Medications can be an important component of effective drug 
abuse treatment for offenders. By allowing the brain to function more 
normally, they enable the addicted person to leave behind a life of 
crime and drug abuse. Although some jurisdictions have found ways to 
successfully implement medication therapy, addiction medications are 
underused in the treatment of drug abusers within the criminal justice 
system, despite evidence of their effectiveness.
Methadone transfer 
on release
Methadone referral only
Methadone pre-  
and post-release
Methadone treatment before and after 
release from prison increases treatment 
retention and reduces drug use
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At 12 months post-release, offenders who had received methadone 
treatment in prison and continued it in the community were significantly 
more likely to enter and stay in treatment and less likely to test 
positive for opioid and cocaine use than participants who received 
counseling and referral to methadone, or those who received 
counseling with transfer to methadone maintenance upon release.
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Effective medications have been developed for treating addiction to 
opiates/heroin and alcohol:
• Opiates/Heroin. Long-term opiate abuse results in a desensitization 
of the brain’s opiate receptors to endorphins, the body’s natural 
opioids. Opioid agonist/partial agonist medications, which act at 
the same receptors as heroin, morphine, and endorphins, tend to 
be well tolerated and can help an individual remain in treatment. 
For example, methadone, an opiate agonist, reduces the craving 
that otherwise results in compulsive use of heroin or other illicit 
opiates. Methadone treatment has been shown to be effective in 
decreasing opiate use, drug-related criminal behavior, and HIV risk 
behavior. Buprenorphine is a partial agonist 
and acts on the same receptors as morphine 
(a full agonist), but without producing the 
same level of dependence or withdrawal 
symptoms. Suboxone is a unique 
formulation of buprenorphine that contains 
naloxone, an opioid antagonist that limits 
diversion by causing severe withdrawal 
symptoms in addicted users who inject it to 
get “high.” It has no adverse effects when taken 
orally, as prescribed.  
     An alternative approach, in previously detoxified opiate users, is 
to use an antagonist medication that blocks the effects of opiates. 
Naltrexone has been available for more than 2 decades, but 
poor compliance in the face of severe cravings and addiction has 
undermined its benefits. An extended-release injectable formulation 
of naltrexone (Vivitrol) was recently approved by the U.S. Food 
and Drug Administration (FDA) for treating opioid addiction. Vivitrol 
requires dosing every few months rather than daily, which stands to 
improve treatment adherence.
• Alcohol. Disulfiram (also known as Antabuse) is an aversion 
therapy that induces nausea if alcohol is consumed. Acamprosate, 
a medication that helps reduce alcohol craving, works by restoring 
normal balance to the brain’s glutamate neurotransmitter system. 
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Naltrexone (and now Vivitrol), which blocks some of alcohol’s 
pleasurable effects and alcohol craving, is also approved by the FDA 
for treatment of alcohol abuse.
11. How can the criminal justice and drug 
abuse treatment systems reduce the spread 
of HIV/AIDS, hepatitis, and other infectious 
diseases among drug abusing offenders?
Individuals involved in the criminal justice system have 
disproportionately high rates of substance use disorders and infectious 
diseases, including HIV/AIDS. In fact, 14 percent of HIV-infected 
individuals in this country pass through the criminal justice system 
each year (Spaulding et al. 2009). Other infectious diseases, such 
as hepatitis B, hepatitis C, and tuberculosis, also are pervasive in the 
criminal justice system. 
This overrepresentation also provides an opportunity to integrate 
treatment and improve outcomes for both substance use disorders 
and infectious diseases. Research shows that treatment for drug 
abuse can lessen the spread of infectious diseases by reducing 
high-risk behaviors like needle-sharing and unprotected sex (Metzger 
et al. 2010). Identifying those who are 
HIV+ and starting them on HAART 
treatment could not only improve 
their health outcomes but also 
decrease HIV spread (Montaner 
et al. 2010). 
It is imperative that offenders 
with infectious diseases be linked 
with community-based medical 
care prior to release. Offenders often 
have difficulty negotiating access to health services and adhering to 
complex treatment protocols following release from prison and jail. 
One study found that simply helping HIV-infected inmates complete 
the paperwork required to get their prescriptions filled upon release 
significantly diminished treatment interruption, although improvement 
was still needed, since fewer than half had filled their prescriptions 
within 2 months of release (Baillargeon et al. 2009). 
The prevalence of AIDS 
is approximately five 
times higher among 
incarcerated offenders 
than in the general 
population.
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Community health, drug treatment, and criminal justice agencies 
should work together to offer education, screening, counseling, 
prevention, and treatment programs for HIV/AIDS, hepatitis, and other 
infectious diseases to offenders returning to the community.
12. What works for offenders with co-occurring 
substance abuse and mental disorders?
It is important to adequately assess mental disorders and to 
address them as part of effective drug abuse treatment. Many types of 
co-occurring mental health problems can be successfully addressed 
in standard drug abuse treatment programs. However, individuals 
with serious mental disorders may require an integrated treatment 
approach designed for treating patients with co-occurring mental and 
substance use disorders. 
Much progress has been made in developing effective medications 
for treating mental disorders, including a number of antidepressants, 
antianxiety agents, mood stabilizers, and antipsychotics. These 
medications may be critical for treatment success with offenders 
who have co-occurring mental disorders such as depression, 
anxiety disorders, bipolar disorder, or schizophrenia. Cognitive-
behavioral therapy can be effective for treating some mental health 
problems, particularly when combined with medications. Contingency 
management can improve adherence to medications, and intensive 
case management may be useful for linking severely mentally ill 
individuals with drug abuse treatment, mental health care, and 
community services. A specialized type of treatment—Modified 
Therapeutic Communities (MTCs)—incorporates features of traditional 
Therapeutic Communities with a special focus on addressing 
co-occurring mental health conditions.
13. Is providing drug abuse treatment to 
offenders worth the financial investment?
In 2007, it was estimated that the cost to society of drug abuse 
was $193 billion (National Drug Intelligence Center [NDIC], 2011), a 
substantial portion of which—$113 billion—is associated with drug-
related crime, including criminal justice system costs and costs borne 
by victims of crime. The cost of treating drug abuse (including health 
FREQUENTLY ASKED QUESTIONS
27
costs, hospitalizations, and government 
specialty treatment) was estimated to be 
$14.6 billion, a fraction of these overall 
societal costs (NDIC, 2011). Drug abuse 
treatment is cost effective in reducing 
drug use and bringing about related 
savings in health care. Treatment also 
consistently has been shown to reduce 
the costs associated with lost productivity, 
crime, and incarceration across various settings 
and populations. The largest economic benefit of treatment is seen 
in avoided costs of crime (incarceration and victimization costs). 
Providing methadone treatment to opioid-addicted prisoners prior to 
their release, for example, not only helps to reduce drug use but also 
avoids the much higher imprisonment costs for drug-related crime 
(see figure).
Even greater economic benefits result from treating offenders with 
co-occurring mental 
health problems 
and substance use 
disorders. Residential 
prison treatment is 
more cost effective 
if offenders attend 
treatment post-
release, according 
to research (Martin 
et al. 1999; Butzin 
2006). Drug courts 
also convey positive 
economic benefits, 
including participant-
earned wages and 
avoided incarceration 
and future crime 
costs.
$4,700
Cost of Treatment
$24,000
Cost of Incarceration
Treating addiction in the criminal justice 
system is cost-effective
The cost of methadone treatment averages 
around $5,000 a year, compared to approximately 
$24,000 for State and Federal prisons to keep 
people confined. Reducing the number of people 
incarcerated for drug use can net huge savings in 
economic and social costs.
Sources: Zarkin et al. 2008 and Warren et al. 2008.
The largest 
economic benefit 
of treatment is 
seen in avoided 
costs of crime.
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14. What are the unique treatment needs 
of women in the criminal justice system?
Although women are incarcerated at far lower rates than men, 
the number and percentage of incarcerated women have grown 
substantially in recent years. Between 2000 and 2008, the number 
of men in prisons and jails grew by only 5 percent, while the number 
of incarcerated women grew by about 15 percent (Sabol et al. 2010). 
Women in prison are likely to have a different set of problems and 
needs than men, presenting particular treatment challenges that may 
call for tailored approaches (Greenfield et al. 2007) (figure).
Incarcerated women in treatment are significantly more likely 
than incarcerated men to have severe substance abuse histories, 
co-occurring mental disorders, and high rates of past treatment for 
both; they also tend to have more physical health problems (Staton 
et al. 2003; Messina et al. 2006). Approximately 50 percent of female 
offenders are likely to have histories of physical or sexual abuse, and 
women are more likely than men to be victims of domestic violence. 
Past or current victimization can contribute to drug or alcohol abuse, 
depression, post-traumatic stress disorder, and criminal activity.
Treatment programs serving both men and women can provide 
effective treatment for their female patients. However, gender-
specific programs may be more effective for female offenders, 
particularly those with histories of trauma and abuse (Pelissier 
et al. 2003). Female offenders are more likely to need medical 
and mental health services, child care services, and assistance 
in finding housing and employment. Following a comprehensive 
assessment, women with mental health disorders should receive 
appropriate treatment and case management, including victim 
services as needed. For female offenders with children, parental 
responsibilities can conflict with their ability to participate in drug 
treatment. Regaining or retaining custody of their children can also 
motivate mothers to participate in treatment. Treatment programs 
may improve retention by offering child care services and parenting 
classes.
FREQUENTLY ASKED QUESTIONS
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15. What are the unique treatment needs 
of juveniles in the criminal justice system?
The U.S. Department of Justice’s Office of Justice Programs 
reports a high rate of drug use among juvenile detainees. One study, 
for example, found that 77 percent of criminal justice-involved youth 
reported substance use (mainly marijuana) in the past 6 months, and 
nearly half of male and female juvenile detainees had a substance use 
disorder (McClelland et al. 2004a; McClelland et al. 2004b).
Arrest rates for drug-related crimes also remain high among 
juveniles. A recent report showed that of the estimated 2.1 million 
juvenile arrests in 2008, approximately 10 percent were for drug abuse 
or underage drinking violations (Puzzanchera 2009).
Juveniles entering the criminal justice system can bring a number 
of serious problems with them—substance abuse, academic failure, 
emotional disturbances, physical health issues, family problems, and 
Incarcerated women have high rates of  
substance abuse, mental disorders,  
and other health problems
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a history of physical or sexual abuse. Girls make up nearly one-third 
of juvenile arrests, a high percentage of whom report some form of 
emotional, physical, or sexual abuse. Effectively addressing these 
problems requires their gaining access to comprehensive assessment, 
treatment, case management, and support services appropriate 
for their age and developmental stage. 
Assessment is particularly important, 
because not all adolescents who have 
used drugs need treatment. For those 
who do, there are several points 
in the juvenile justice continuum 
where treatment has been integrated, 
including juvenile drug courts, 
community-based supervision, juvenile 
detention, and community re-entry.
Families play an important role in the recovery of substance abusing 
juveniles, but this influence can be either positive or negative. Parental 
substance abuse or criminal involvement, physical or sexual abuse 
by family members, and lack of parental involvement or supervision 
are all risk factors for adolescent substance abuse and delinquent 
behavior. Thus, the 
effective treatment of 
juvenile substance 
abusers often requires a 
family-based treatment 
model that targets 
family functioning 
and the increased 
involvement of family 
members. Effective 
adolescent treatment 
approaches include 
multisystemic therapy, 
multidimensional family 
therapy, and functional 
family therapy. These 
interventions show promise in strengthening families and decreasing 
juvenile substance abuse and delinquent behavior.
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Juvenile offenders
Virtually every juvenile offender should 
be screened for drug abuse and mental 
disorders, and receive an intervention:
•  Treatment for those who are dependent on 
alcohol or drugs, or mentally ill.
•  Drug abuse prevention for those who are not. 
•  HIV prevention or treatment as needed.
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RESOURCES
Many resources 
are available on the 
Internet. 
The following are useful links:
General Information
NIDA Web site: www.drugabuse.gov
General Inquiries: NIDA Public Information Office 301–443–1124
Federal Resources
Bureau of Justice Assistance (BJA) 
Substance Abuse Programs
www.bja.gov/Topic.
aspx?Topic_ID=8
Bureau of Justice Statistics (BJS) 
Statistics on Drugs and Crime
www.bjs.ojp.usdoj.gov/
content/dcf/contents.cfm
Center for Substance Abuse  
 Treatment (CSAT) 
Substance Abuse and Mental Health 
 Services Administration (SAMHSA)
www.beta.samhsa.gov/
about-us/who-we-are/
offices-centers/csat
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Federal Resources (continued)
Federal Bureau of Prisons (BOP)
Substance Abuse Treatment
www.bop.gov/inmates/
custody_and_care/sub-
stance_abuse_treatment.
jsp
National Criminal Justice 
 Reference Service (NCJRS)
www.ncjrs.gov
National Institute on Alcohol Abuse 
 and Alcoholism (NIAAA)
www.niaaa.nih.gov
National Institute of Corrections (NIC) www.nicic.org
National Institute of Justice (NIJ) www.nij.gov
National Institute of Mental Health (NIMH) www.nimh.nih.gov
Office of Applied Studies (OAS) 
Substance Abuse and Mental Health 
 Services Administration (SAMHSA)
 www.samhsa.gov/data
Office of Justice Programs (OJP)  www.ojp.gov
Office of Juvenile Justice and 
 Delinquency Prevention (OJJDP)
www.ojjdp.gov
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